HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clariant TEA extension

This article was originally published in The Rose Sheet

Executive Summary

FDA grants piroctone olamine manufacturer's request for extension of public comment period for anti-dandruff ingredient safety and efficacy review to August 16. In a May 19 Federal Register 1notice, the agency said it "considers an extension of time for submission of data, information and general comments concerning the safety and effectiveness of piroctone olamine to be in the public interest." Clariant had requested the 90-day extension to assemble a "more comprehensive" submission for the ingredient in an April 16 letter to FDA (2"The Rose Sheet" May 10, 2004, In Brief)...
Advertisement
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

RS012146

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel